73 FR 219 pgs. 66913-66915 - Government-Owned Inventions; Availability for Licensing
Type: NOTICEVolume: 73Number: 219Pages: 66913 - 66915
FR document: [FR Doc. E8-26794 Filed 11-10-08; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: National Institutes of Health
Official PDF Version: PDF Version
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY:
National Institutes of Health, Public Health Service, HHS.
ACTION:
Notice.
SUMMARY:
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
ADDRESSES:
Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
Microarray for Detection and Subtyping of Human Influenza Viruses
Description of Technology: Available for licensing and commercial development are a novel influenza virus microarray and methods for using the microarray for the identification of existing and new types and subtypes of human influenza viruses. There are three types of influenza viruses, type A, B and C. Influenza types A or B viruses cause epidemics of disease almost every winter, with type A causing a major pandemic periodically. Influenza type A viruses are further divided into subtypes based on two proteins on the surface of the virus. These proteins are called hemagglutinin (H) and neuraminidase (N). There are 16 known HA subtypes and 9 known NA subtypes of influenza A viruses. Each subtype may have different combinations of H and N proteins. Although there are only three known A subtypes of influenza viruses (H1N1, H1N2, and H3N2) currently circulating among humans, many other different strains are circulating among birds and other animals and these viruses do spread to humans occasionally. There is a requirement for sensitive and rapid diagnostic techniques in order to improve both the diagnosis of infections and the quality of surveillance systems. This microarray platform tiles the genomes of all types/subtypes of influenza viruses, and is capable of correctly identifying all 3 types/subtypes of influenza viruses from an influenza vaccine sample.
More specifically, the invention consists of: (1) Microarrays comprising a solid support with a plurality of n-mer influenza viral nucleotide segments of influenza Types A, B and C, including each respective subtype, and (2) methods of detecting and identifying known and unknown influenza viral types and subtypes by: (a) Using hybridization microarrays to known influenza viral nucleotide sequences, (b) sequencing the nucleotides which hybridize to the microarrays and (c) analyzing the hybridized sequences using existing databases, thus identifying existing or new subtypes of influenza viruses.
Applications: Detection and identification of human influenza viruses; Efficient discovery of new subtypes of influenza viruses; Diagnosis of influenza outbreaks.
Development Status: This microarray platform was capable of correctly identifying all 3 types/subtypes of influenza viruses from an influenza vaccine sample.
Inventors: Xiaolin Wu, Cassio S. Baptista, Elizabeth Shannon, and David J. Munroe (NCI).
Patent Status:
• U.S. Provisional Application No. 60/857,695 filed 07 Nov 2006 (HHS Reference No. E-208-2006/0-US-01);
• U.S. Patent Application No. 11/936,530 filed 07 Nov 2007 (HHS Reference No. E-208-2006/0-US-02);
• PCT Application No. PCT/US2007/023448 filed 07 Nov 2007 (HHS Reference No. E-208-2006/0-PCT-03).
Licensing Status: Available for non-exclusive or exclusive licensing.
Licensing Contact: Jeffrey A. James, PhD; 301-435-5474; jeffreyja@mail.nih.gov.
Novel Infrared (IR)-Transparent Hydrophilic Membrane That Can be Used for Filtration, Printing or Microarrays, and Cultivation of Bacteria and Other Microorganisms for Reagent-Free IR Spectroscopic Identification
Description of Technology: Available for licensing and commercial development is a novel, disposable infrared (IR)-transparent, microporous, plasma treated polyethylene hydrophilic membrane, as well as methods for making and using this membrane to identify bacterial and other micoorganism impurities in food using IR spectroscopy. Further applications include: Filtering dilute aqueous bacterial suspensions, and growing bacterial colonies when the PE membrane is placed over an agar medium and incubated. The patent also describes a novel high-throughout technique, as an alternative to manual filtration, where the PE membrane is used for microarray printing of intact microorganisms in pre-enriched medium on the treated PE substrate. Furthermore, the invention relates to a method of detecting mixtures of food-borne pathogens E. sakazakii and K. pneumonia , by using the treated PE membranes. Because this unique membrane is transparent to infrared light, isolated microcolonies of bacterial cells grown on this PE substrate can be fingerprinted directly by IR microspectroscopy, followed by multivariate analysis for the identification of the pathogens. The method can be applied to other cell types as well.
This novel membrane and its applications offer an advantage over existing tests in that it can be used to rapidly identify presumptive pathogen colonies, and can be used in screening tests for a large number of pathogens, as well as various microorganisms and cell types. It can also be used to isolate microorganisms from aqueous suspensions as well as spores, including airborne ones.
Inventors: Magdi M. Mossoba and Sufian Al-Khaldi (FDA).
Patent Status:
• U.S. Patent Application No. 11/343,561 filed 30 Jan 2006 (HHS Reference No. E-174-2005/0-US-01);
• U.S. Patent Application No. 12/150,048 filed 23 Apr 2008 (HHS Reference No. E-174-2005/0-US-02).
Licensing Status: Available for non-exclusive or exclusive licensing.
Licensing Contact: Jeffrey A. James, PhD; 301-435-5474; jeffreyja@mail.nih.gov.
Molecular Motors Powered by Proteins
Description of Technology: The technology available for licensing and commercial development relates to molecular motors powered by proteins. Some implementations describe a molecular motor in which multiple concentric cylinders or nested cones rotate around a common longitudinal axis. Opposing complementary surfaces of the cylinders or cones are coated with complementary motor protein pairs, such as actin and myosin. The actin and myosin interact with one another in the presence of ATP to rotate the cylinders or cones relative to one another, and this rotational energy is harnessed to produce work. Speed of movement is controlled by the concentration of ATP and the number of nested cylinders or cones. The length of the cylinders or cones can also be used to control the power generated by the motor.
Another configuration forms the motor out of a set of stacked disks, much like CDs on a spindle. The advantage of this form is extreme simplicity of construction compared to the nested cylinders or cones. In yet another configuration, which has aspects of both of the previous forms, the surfaces are broken into annular rings in order to overcome that the inner surfaces rotate at a different rate than the outer surfaces. This belt form may ultimately be used in molecular manufacturing.
Applications:
• Supplying power to prosthetic implants and other medical devices without external power sources.
• Many other applications that could use a motor in other biotechnological areas, in addition to the medical applications.
• The inventions can be implemented on either a microscopic or macroscopic scale.
Development Status: Very early stage of development.
Inventors: Thomas D. Schneider and Ilya G. Lyakhov (NCI).
Relevant Publications: "Molecular motor", Patent Publication Nos. WO 2001/009181 A1, published 02/08/2001; CA 2380611A1, published 02/08/2001; AU 6616600A, published 02/19/2001; EP 1204680A1, published 05/15/2002; and U.S. 20020083710, published 07/04/2002.
Patent Status:
• HHS Reference No. E-018-1999/0-International Application Number PCT/US 2000/20925 filed 31 Jul 2000; granted Application AU 2002/18688 B2, and the corresponding European and Canadian applications being prosecuted, all entitled "Molecular Motor"
• HHS Reference No. E-018-1999/1-U.S. Patent No. 7,349,834 issued 25 Mar 2008, and U.S. Patent Application No. 12/011,239 filed 24 Jan 2008, both entitled "Molecular Motor"
Licensing Status: Available for non-exclusive or exclusive licensing.
Licensing Contact: Jeffrey A. James, PhD; 301-435-5474; jeffreyja@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute, Center for Cancer Research Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the Molecular Rotation Engine. Please contact John D. Hewes, PhD at 301-435-3121 or hewesj@mail.nih.gov for more information.
Dated: November 3, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer,National Institutes of Health.
[FR Doc. E8-26794 Filed 11-10-08; 8:45 am]
BILLING CODE 4140-01-P